Optimization of M 3 Antagonist–PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c01012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Andrea Rizzi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Chiesi Farmaceutici S.p.A., Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Ministero dello Sviluppo Economico.
Themen: COPD
Abstract (Originalsprache)
Aiming at the inhaled treatment of pulmonary diseases, the optimization process of the previously reported MAPI compound 92a is herein described. The project was focused on overcoming the chemical stability issue and achieving a balanced bronchodilator/anti-inflammatory profile in rats in order to be confident in a clinical effect without having to overdose at one of the biological targets. The chemical strategy was based on fine-tuning of the substitution pattern in the muscarinic and PDE4 structural portions of the dual pharmacology compounds, also making use of the analysis of a proprietary crystal structure in the PDE4 catalytic site. Compound 10f was identified as a chemically stable, potent, and in vivo balanced MAPI lead compound, as assessed in bronchoconstriction and inflammation assays in rats after intratracheal administration. After the in-depth investigation of the pharmacological and solid-state profile, 10f proved to be safe and suitable for development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chiesi Farmaceutici S.p.A., Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy.
- Charles River Discovery Research Services UK Ltd., Chesterford Research Park, Saffron Walden CB10 1XL, United Kingdom.
ORCID-Profile: Andrea Rizzi, Elisabetta Armani
Förderung
- Ministero dello Sviluppo Economico
Zitieren
APA
Rizzi, A., Amari, G., Pivetti, F., Delcanale, M., Amadei, F., Pappani, A., Fornasari, L., Villetti, G., Marchini, G., Pisano, A. R., Pitozzi, V., Pittelli, M. G., Trevisani, M., Salvadori, M., Cenacchi, V., Fioni, A., Puccini, P., Civelli, M., Patacchini, R., …, & Armani, E. (2023). Optimization of M 3 Antagonist–PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01012
Vancouver
Rizzi A, Amari G, Pivetti F, Delcanale M, Amadei F, Pappani A, et al. Optimization of M 3 Antagonist–PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01012
BibTeX
@article{Rizzi2023,
author = {Rizzi, Andrea and Amari, Gabriele and Pivetti, Fausto and Delcanale, Maurizio and Amadei, Francesco and Pappani, Alice and Fornasari, Luca and Villetti, Gino and Marchini, Gessica and Pisano, Anna Rita and Pitozzi, Vanessa and Pittelli, Maria Gloria and Trevisani, Marcello and Salvadori, Michela and Cenacchi, Valentina and Fioni, Alessandro and Puccini, Paola and Civelli, Maurizio and Patacchini, Riccardo and Baker-Glenn, Charles and Van de Poël, Hervé and Blackaby, Wesley and Nash, Kevin and Armani, Elisabetta},
title = {Optimization of M 3 Antagonist–PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c01012}
}
EUVIMED